Evidence map›Paper›PMID 42455072›Full record

ArticleDiabetes2026

Developmental Control of DNA Damage Responses in α- and β-Cells Shapes the Selective β-Cell Susceptibility in Diabetes.

Sneha S Varghese, Alessandro Giovanni Hernandez-De La Peña, Liu Wang, Victor Ruiz, Wilma Tixi, Aparamita Pandey, Laura Anchondo, Amy Chiu, Xiwei Wu, Senta K Georgia and 4 more

Abstract read
In one paragraph

Article in Diabetes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Sneha S VargheseDepartment of Translational Research and Cellular Therapeutics, Arthur Riggs Diabetes and Metabolism Research Institute, City of Hope, Duarte, CA.
Alessandro Giovanni Hernandez-De La PeñaBiomedical and Biological Sciences Program, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Liu WangDepartment of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine, Scottsdale, AZ.
Victor RuizDepartment of Translational Research and Cellular Therapeutics, Arthur Riggs Diabetes and Metabolism Research Institute, City of Hope, Duarte, CA.
Wilma TixiDepartment of Translational Research and Cellular Therapeutics, Arthur Riggs Diabetes and Metabolism Research Institute, City of Hope, Duarte, CA.
Aparamita PandeyDivision of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA.
Laura AnchondoDepartment of Molecular and Cellular Endocrinology, Arthur Riggs Diabetes and Metabolism Research Institute, City of Hope, Duarte, CA.
Amy ChiuDepartment of Translational Research and Cellular Therapeutics, Arthur Riggs Diabetes and Metabolism Research Institute, City of Hope, Duarte, CA.
Xiwei WuIntegrative Genomics Core, City of Hope, Duarte, CA.
Senta K GeorgiaDepartment of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA.ORCID 0000-0002-2016-7866
Hung-Ping ShihDepartment of Translational Research and Cellular Therapeutics, Arthur Riggs Diabetes and Metabolism Research Institute, City of Hope, Duarte, CA.
Zong WeiDepartment of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine, Scottsdale, AZ.ORCID 0000-0002-4691-0101
Supriyo BhattacharyaDepartment of Diabetes and Cancer Discovery Science, Arthur Riggs Diabetes and Metabolism Research Institute, City of Hope, Duarte, CA.
Sangeeta DhawanDepartment of Translational Research and Cellular Therapeutics, Arthur Riggs Diabetes and Metabolism Research Institute, City of Hope, Duarte, CA.ORCID 0000-0002-1562-7899

Funding

The Human Pancreas Analysis Program for Type 2 DiabetesU01DK123594 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Robert Babak Faryabi, KLAUS H KAESTNER · 2019 to 2026
$25.0M
Penn integrated Human Pancreas procurement and Analysis ProgramUC4DK112217 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI BETTS, MICHAEL R, FELDMAN, MICHAEL D · 2016 to 2020
$17.8M
Integrated Islet Distribution Program (U24) - 2021U24DK098085 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Carmella Evans-Molina, Joyce Carol Niland · 2021 to 2026
$17.8M
Supplement to Integrated Program for Human Pancreas Procurement and AnalysisUC4DK112232 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ATKINSON, MARK A., POWERS, ALVIN C · 2016 to 2020
$8.4M
Human Pancreas Analysis Program-T2DU01DK123716 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ATKINSON, MARK A., BOTTINO, RITA · 2019 to 2024
$6.6M
Regulation of beta-cell homeostasis by DNA methylation and hydroxymethylation.R01DK120523 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI DHAWAN, SANGEETA · 2019 to 2023
$2.2M
Microenvironmental cues control pancreas cell fate and beta-cell maturationR01DK119590 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI SHIH, HUNG-PING · 2018 to 2022
$2.1M
Role of SIRT7 in the Pancreatic Beta CellsR01DK132651 · NIDDK · MAYO CLINIC ARIZONA · PI Zong Wei · 2022 to 2026
$2.1M
Beta cell dysfunction as an acute and a post acute sequelae of COVID19R01DK133504 · NIDDK · CHILDREN'S HOSPITAL OF LOS ANGELES · PI GEORGIA, SENTA K · 2022 to 2024
$1.6M
Epigenetic regulation of genomic stability in beta-cell homeostasisR01DK140088 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Sangeeta Dhawan · 2025 to 2026
$1.3M
Epigenetic basis of physiology and pathophysiology of glucocorticoids action on pancreatic beta cellsR01DK143607 · NIDDK · MAYO CLINIC ARIZONA · PI ALEKSEY V MATVEYENKO, Zong Wei · 2026 to 2026
$807k
Defining heterogeneity of stress-induced beta cell senescence programs in type 1 diabetesU01DK143458 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI Sangeeta Dhawan, Feyza Engin · 2026 to 2026
$758k
Arthur Riggs Diabetes and Metabolism Research Institute Pilot Award N/ABeatson Foundation #2026-010California Institute for Regenerative Medicine EDUC4-12772NIDDK NIH HHS R01 DK119590NIDDK NIH HHS R01DK119590NIDDK NIH HHS R01 DK120523NIDDK NIH HHS R01 DK132651NIDDK NIH HHS R01DK132651NIDDK NIH HHS R01 DK133504NIDDK NIH HHS R01DK133504NIDDK NIH HHS R01 DK140088NIDDK NIH HHS R01DK140088NIDDK NIH HHS R01 DK143607NIDDK NIH HHS R01DK143607NIDDK NIH HHS U01 DK123594NIDDK NIH HHS U01 DK123716NIDDK NIH HHS U01 DK143458NIDDK NIH HHS U01DK143458NIDDK NIH HHS U24 DK098085NIDDK NIH HHS U24DK098085NIDDK NIH HHS UC4 DK112217NIDDK NIH HHS UC4 DK112232
6 · The paper itself

Abstract

Accumulation of DNA damage drives β-cell dysfunction, senescence, and death in type 1 and type 2 diabetes. Although α-cell dysfunction also contributes to disease pathology, α-cells remain remarkably resistant to senescence and increased cell death under diabetogenic stress. The mechanisms underlying these differential responses to diabetogenic stress, particularly differences in their DNA damage vulnerability, remain unclear. We demonstrate that replication introduces a window of genomic vulnerability in both α- and β-cells during neonatal growth, with α-cells exhibiting higher replication rates and DNA damage. We show that neonatal β-cells resolve DNA damage more efficiently during mitosis and favor error-free repair, whereas α-cells compensate for their greater DNA-damage vulnerability through increased cellular turnover. Using mouse models of overnutrition and diabetes, we show that β-cells exhibit greater vulnerability to terminal DNA damage and impaired repair capacity under diabetogenic stress, with compensatory replication amplifying this vulnerability. We demonstrate that developmental and postnatal epigenetic programs shape the differential DNA damage vulnerability of postnatal β- and α-cells. Loss of de novo DNA methyltransferase Dnmt3a in pancreatic progenitors selectively increases the DNA damage vulnerability of β-cells from neonatal growth through adulthood. Complementing this developmental process, enhancer analyses reveal lineage-specific DNA damage response regulatory landscapes that are remodeled in β-cells under metabolic stress. Collectively, our findings uncover novel developmental mechanisms that shape the distinct DNA damage responses of postnatal β- and α-cells during growth and diabetes. ARTICLE HIGHLIGHTS: Mechanisms underlying the differential susceptibility of pancreatic β- and α-cells to diabetogenic stress remain unclear. We investigated whether replication, repair fidelity, and developmental epigenetic programs determine the vulnerability of postnatal β- and α-cells to DNA damage, a key driver of β-cell failure in diabetes. Replication introduces DNA damage vulnerability in both neonatal β- and α-cells, yet β-cells resolve damage more efficiently. Loss of DNA methyltransferase 3a in pancreatic progenitors selectively heightens β-cell DNA damage vulnerability that persists into adulthood. Moreover, diabetogenic stress preferentially compromises β-cell repair fidelity. These findings reveal how developmental programs shape β-cell resilience and may influence lifelong diabetes risk.

Indexed as

Diabetes Mellitus, ExperimentalDNA DamageGlucagon-Secreting CellsInsulin-Secreting CellsAnimalsAnimals, NewbornDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNA RepairDNA ReplicationEpigenesis, GeneticMaleMiceMice, Inbred C57BLDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3A

Identifiers

PMID42455072
PMCPMC13493214

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.